RxMP's microparticles may be safer hemostats by speeding, not starting clotting
RxMP Therapeutics LLC is developing microparticles harvested from red blood cells to mitigate excessive bleeding during surgery or trauma by promoting clotting at sites of bleeding without instigating unwanted coagulation.
Available hemostatics used for acute bleeding pose significant safety risks. Trasylol aprotinin has a black box for risk of fatal anaphylaxis, renal dysfunction and a possible association with increased mortality, and is available in the U.S. for investigational use only. NovoSeven eptacog alfa and tranexamic acid are sometimes used off label to treat acute bleeding,